Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising drug class for the treatment of diabetic kidney disease. Developed originally as glucose-lowering drugs by enhancing urinary glucose excretion, these drugs also lower many other renal and cardiovascular risk factors such as body weight, blood pressure, albuminuria, and uric acid. Results from the EMPA-REG OUTCOME and CANVAS trials show that these salutary effects translate into a reduction in cardiovascular outcomes and have the potential to delay the progression of kidney function decline. This review summarizes recent studies on the mechanisms and rationale of renoprotective effects.Recent Findings Effects of SGLT-2 inhibitors on the kidney a...
During the last years a new group of medicines, named sodium-glucose co-transporter 2 (SGLT2) inhibi...
The management of type 2 diabetes (T2D) involves decreasing plasma glucose levels and reducing cardi...
This year the medical community was pleasantly surprised by the results of the first large outcome t...
Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising dr...
Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising dr...
Purpose of Review: This review offers a critical narrative evaluation of emerging evidence that sodi...
Background: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering ...
Diabetes increases the risk of adverse cardiovascular and renal events. Recently, sodium-glucose co-...
Objective: To review glucose-lowering efficacy and changes in renal function associated with sodium-...
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease in the United States ...
As the prevalence of diabetic kidney disease (DKD) continues to rise, so does the need for a novel t...
SGLT2; Chronic kidney disease; Diabetic nephropathySGLT2; Malaltia renal crònica; Nefropatia diabèti...
Prevalence of type 1 diabetes mellitus (T1DM) is globally continuously increasing. T1DM is accompani...
Sodium‐glucose co-transporter 2 (SGLT2) inhibitors have recently emerg ed as an effective means to p...
During the last years a new group of medicines, named sodium-glucose co-transporter 2 (SGLT2) inhibi...
The management of type 2 diabetes (T2D) involves decreasing plasma glucose levels and reducing cardi...
This year the medical community was pleasantly surprised by the results of the first large outcome t...
Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising dr...
Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising dr...
Purpose of Review: This review offers a critical narrative evaluation of emerging evidence that sodi...
Background: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering ...
Diabetes increases the risk of adverse cardiovascular and renal events. Recently, sodium-glucose co-...
Objective: To review glucose-lowering efficacy and changes in renal function associated with sodium-...
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease in the United States ...
As the prevalence of diabetic kidney disease (DKD) continues to rise, so does the need for a novel t...
SGLT2; Chronic kidney disease; Diabetic nephropathySGLT2; Malaltia renal crònica; Nefropatia diabèti...
Prevalence of type 1 diabetes mellitus (T1DM) is globally continuously increasing. T1DM is accompani...
Sodium‐glucose co-transporter 2 (SGLT2) inhibitors have recently emerg ed as an effective means to p...
During the last years a new group of medicines, named sodium-glucose co-transporter 2 (SGLT2) inhibi...
The management of type 2 diabetes (T2D) involves decreasing plasma glucose levels and reducing cardi...
This year the medical community was pleasantly surprised by the results of the first large outcome t...